We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement

Product News   Apr 20, 2021

 
ERS Genomics and NUVISAN ICB Sign CRISPR/Cas9 License Agreement
FURTHER INFORMATION
 
 
Advertisement
 

Related Product News

ERS Genomics and GenScript Biotech Corporation Sign CRISPR/Cas9 License Agreement

Product News

ERS Genomics Limited and GenScript Biotech Corporation have announced a non-exclusive license agreement granting GenScript access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

READ MORE

Phico Therapeutics Raises £7 million Investment

Product News

Phico Therapeutics Ltd has announced £7 million in new investment. The financing was led by the UK’s most active growth capital investor, BGF which invested £3 million and was joined by other existing Phico investors.

READ MORE

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2(R)

Product News

Orgenesis Inc. announces it has been granted Investigational Device Exemption (IDE) approval by the United States Food and Drug Administration (FDA) to conduct a first-in-human feasibility study of the Tissue Genesis Icellator2(R) to treat Acute Respiratory Distress Syndrome (ARDS) resulting from COVID-19 infection.

READ MORE

Like what you just read? You can find similar content on the communities below.

Drug Discovery Genomics Research

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE